CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $0, lower than 95% of all stocks globally
- FinancialsLow earnings quality
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
393.35MUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
0.9670xvs all stocks
52-Week Change
60.79%vs all stocks
Market Capitalization
393.35MUSDvs all stocks (USD)
Enterprise Value
360.55MUSDvs all stocks (USD)
Forward P/E
-8.10xvs Biotechnology peers
Price to Book (MRQ)
8.13xvs Biotechnology peers
Enterprise to EBITDA
-9.83xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-49.96%vs Biotechnology peers
Return on Equity (TTM)
-86.47%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Jul 18, 2026Gross Profit (TTM)
0.00USDvs all stocks (USD)
EBITDA (TTM)
-36.69MUSDvs all stocks (USD)
Net Income (TTM)
-35.10MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-31.00MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-18.01MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 18, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-34.40MUSDvs all stocks (USD)
Pre-tax Income
-32.74MUSDFY2025 · Dec 31, 2025Income Tax Expense
28.00KUSDFY2025 · Dec 31, 2025Net Income
-32.77MUSDFY2025 · Dec 31, 2025EBIT
-34.40MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-34.35MUSDFY2025 · Dec 31, 2025Research & Development
24.61MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
9.78MUSDFY2025 · Dec 31, 2025EPS (Basic)
-0.7000USDFY2025 · Dec 31, 2025EPS (Diluted)
-0.7000USDFY2025 · Dec 31, 2025Basic Shares Outstanding
46.98MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
46.98MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-32.77MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-28.28MUSDFY2025 · Dec 31, 2025Free Cash Flow
-28.32MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
15.65MUSDFY2025 · Dec 31, 2025Income Tax Paid
28.00KUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-32.77MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
43.00KUSDFY2025 · Dec 31, 2025Stock-based Compensation
3.85MUSDFY2025 · Dec 31, 2025Other Non-cash Items
82.00KUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-22.00KUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
535.00KUSDFY2025 · Dec 31, 2025Capital Expenditures
-40.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-59.28MUSDFY2025 · Dec 31, 2025Sale of Investments
57.13MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-2.19MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-10.00KUSDFY2025 · Dec 31, 2025Other Financing Charges
-400.00KUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
42.87MUSDFY2025 · Dec 31, 2025Shares Outstanding
53.88MSharesUpdated Jul 18, 2026Float Shares
28.77MSharesUpdated Jul 18, 2026Shares Short
5.21MSharesUpdated Jul 18, 2026Short Ratio
22.43daysvs all stocks
Short % of Shares Outstanding
14.40%vs all stocks
% Held by Insiders
27.74%vs all stocks
% Held by Institutions
37.85%vs all stocks
Total Cash (MRQ)
51.33MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
0.9530USDUpdated Jul 18, 2026Total Debt (MRQ)
212.00KUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0045xvs Biotechnology peers
Current Ratio (MRQ)
9.11xvs Biotechnology peers
Book Value per Share (MRQ)
0.8770USDUpdated Jul 18, 2026Total Assets
61.37MUSDvs all stocks (USD)
Total Current Assets
60.63MUSDFY2025 · Dec 31, 2025Total Liabilities
5.26MUSDFY2025 · Dec 31, 2025Total Non-current Assets
742.00KUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
128.00KUSDFY2025 · Dec 31, 2025Total Current Liabilities
5.13MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
15.65MUSDFY2025 · Dec 31, 2025Other Short-term Investments
44.24MUSDFY2025 · Dec 31, 2025Accounts Receivable
8.00KUSDFY2025 · Dec 31, 2025Accounts Payable
1.48MUSDFY2025 · Dec 31, 2025Short-term Debt
112.00KUSDFY2025 · Dec 31, 2025Long-term Debt
128.00KUSDFY2025 · Dec 31, 2025Common Stock (Book)
0.00USDFY2025 · Dec 31, 2025Retained Earnings
-172.77MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
56.11MUSDvs all stocks (USD)
52-Week Low
4.01USDUpdated Jul 18, 202652-Week High
10.42USDUpdated Jul 18, 202652-Week Change
60.79%vs all stocks
Beta
0.9670xvs all stocks
50-Day MA
6.36USDUpdated Jul 18, 2026200-Day MA
7.20USDUpdated Jul 18, 2026Avg 10-Day Volume
213.35KSharesUpdated Jul 18, 2026Avg 30-Day Volume
234.10KSharesUpdated Jul 18, 2026Diluted EPS (TTM)
-0.7100USDUpdated Jul 18, 2026Other Income / Expense
1.66MUSDFY2025 · Dec 31, 20251 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Multi-Year Debt Decrease With Cash Near Total Debt And Equity
Long-term debt down in each of four years, and cash now covers most or all of what is left.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.77
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
Foresee Pharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Kontour Xi'an Medical Technology Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Emergent BioSolutions Inc.
Tier 1ProductionApproval-Gated PipelineRule
NIOX Group plc
Tier 1ProductionApproval-Gated PipelineRule
Blau Farmacêutica S.A.
Tier 1ProductionApproval-Gated PipelineRuleFlow
PureTech Health plc
Tier 1ProductionApproval-Gated PipelineRiskInterface
Sutro Biopharma, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Atea Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shenzhen Bioeasy Biotechnology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Enanta Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Nanjing Xinjiekou Department Store Co. Ltd.
1 interpretationMulti-Year Debt Decrease With Cash Near Total Debt And Equity
Halo Microelectronics Co., Ltd.
1 interpretationMulti-Year Debt Decrease With Cash Near Total Debt And Equity
Olaplex Holdings, Inc.
1 interpretationMulti-Year Debt Decrease With Cash Near Total Debt And Equity